Year: 2023

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical...

NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin

CARMEL, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell...

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug....

error: Content is protected !!